Verrica Pharmaceuticals Raises $50 Million in Private Placement Financing
Reuters
Nov 24
Verrica Pharmaceuticals Raises $50 Million in Private Placement Financing
Verrica Pharmaceuticals Inc. has announced a private investment in public equity $(PIPE)$ financing, raising approximately $50 million in gross proceeds before placement agent fees and offering expenses. The financing is anchored by Caligan Partners LP and PBM Capital, along with participation from new and existing investors. Caligan Partners will be entitled to designate a new member to Verrica's Board of Directors. Verrica intends to use $35 million of the net proceeds to fully repay its outstanding obligations under its Credit Agreement with OrbiMed, with the remainder allocated to working capital and general corporate purposes. The financing is expected to close on or about November 25, 2025, subject to customary closing conditions. With the proceeds from this financing and existing cash, Verrica expects to fund its operations into mid-2027. TD Cowen is acting as the sole placement agent for the PIPE financing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9590916-en) on November 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.